Arcus Biosciences News

Despite Lacking Profits Arcus Biosciences (NYSE:RCUS) Seems To Be On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much

Simply Wall St01:43

Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024

Yahoo Finance01:38

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the

BusinesswireMay 10 04:35

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 10 03:48

Earnings Call Summary | Arcus Biosciences(RCUS.US) Q1 2024 Earnings Conference

The following is a summary of the Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arcus Biosciences reported that they have over $1 billion of cash on hand, which

Futu NewsMay 9 22:02 · Conference Call

Arcus Biosciences Price Target Maintained With a $30.00/Share by Wedbush

Arcus Biosciences Price Target Maintained With a $30.00/Share by Wedbush

Dow JonesMay 9 21:00

Wedbush: The Arcus Biosciences (RCUS.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $30.00.

Wedbush: The Arcus Biosciences (RCUS.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $30.00.

Zhitong FinanceMay 9 20:50

Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.

BenzingaMay 9 20:50

Arcus Biosciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 87.5% Wedbush → $30 Reiterates Outperform → Outperform 03/25/2024 212.5% Truist Securities → $5

BenzingaMay 9 20:49

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)

TipRanksMay 9 20:04

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

TipRanksMay 9 20:02

Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties

TipRanksMay 9 18:05

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)

TipRanksMay 9 15:30

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 09:55

Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.0

BenzingaMay 9 05:31

Arcus Biosciences | 10-Q: Quarterly report

Futu NewsMay 9 04:15 · Announcements

Arcus Biosciences 1Q Rev $145M >RCUS

Arcus Biosciences 1Q Rev $145M >RCUS

Dow JonesMay 9 04:09

Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M

04:03 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M

MT NewswiresMay 9 04:03

Arcus Biosciences 1Q Loss $4M >RCUS

Arcus Biosciences 1Q Loss $4M >RCUS

Dow JonesMay 9 04:02

Arcus Biosciences 1Q Loss/Shr 5c >RCUS

Arcus Biosciences 1Q Loss/Shr 5c >RCUS

Dow JonesMay 9 04:02